Novo Nordisk
Research

Novo reports about 21% weight loss for lower-dose CagriSema
Novo Nordisk says its investigational CagriSema combination produced estimated average weight loss of 20.7% and 21.0% after 68 weeks at two lower doses in the REDEFINE 9…

Microsoft rebuilds Novo clinical data agent as hosted Foundry service
Microsoft and Novo Nordisk have reimplemented an AI agent for secondary analysis of clinical trial data as a hosted agent in Microsoft Foundry. Microsoft says the move…
BusinessOpenAI acquires Orchestra Bio to bring AI agents into drug development
OpenAI has acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development. The company will merge Orchestra's team and…

NVIDIA Partners With Novo Nordisk and DCAI on Drug Discovery
NVIDIA has announced a partnership with Novo Nordisk and DCAI aimed at advancing drug discovery. The announcement was published on NVIDIA's newsroom on 28 September 2026…